IPH Innate Pharma S.A.

EPA · FR · Healthcare · Biotechnology · innate-pharma.com

1.320EUR+0.30%Mkt Cap: 160.27M $P/E: —Today

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap160.27M USD

Enterprise Value144.15M USD

Revenue (TTM)10.66M USD

Gross Profit-32.79M USD

Net Income (TTM)-53.45M USD

Revenue/Share0.10 EUR

Last Price1.320 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees120

CountryFR

SectorHealthcare

IndustryBiotechnology

ISINFR0010331421

Valuation

P/E (Trailing)—

P/E (Forward)0.61

PEG—

EV/EBITDA-2.82

EV/Revenue13.52

P/S14.99

P/B-3.05

EPS (TTM)-0.51

EPS (Forward)2.15

52W Range

1.03022% of range2.330

52W High2.330 EUR

52W Low1.030 EUR

Profitability

Gross Margin0.00%

Oper. Margin-335.70%

EBITDA Margin0.00%

Profit Margin-1764.51%

ROE226.58%

ROA-78.41%

Growth

Revenue Growth16.50%

Earnings Growth—

Cash Flow & Leverage

Operating CF-35.39M USD

CapEx (TTM)2.56M USD

FCF Margin-295.30%

FCF Yield-19.64%

Net Debt10.12M USD

Net Debt/EBITDA-0.20

Balance Sheet

Debt/Equity-1.04

Current Ratio0.60

Quick Ratio0.47

Book Value/Sh-0.43 EUR

Cash/Share0.12 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)5.900 EUR

Upside (mean)+347.0%

Target Range5.600 EUR – 6.200 EUR

5.600+347.0% to mean6.200

# Analysts2

Ownership

Shares Out.111.70M

Float70.45M

Insiders17.46%

Institutions10.86%

Technical

SMA 501.666 (-20.8%)

SMA 2001.500 (-12.0%)

Beta0.88

S&P 52W Chg14.58%

Avg Vol (30d)296.18K

Avg Vol (10d)271.88K

Technical Indicators

RSI (14)25.9

MACD-0.0973

MACD Signal-0.0773

MACD Hist.-0.0200

BB Upper1.751 EUR

BB Middle1.524 EUR

BB Lower1.298 EUR

BB Width29.73%

ATR (14)0.0728 EUR

Vol Ratio (20d)0.79x